Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors
Conditions
Interventions
RMC-4630
Locations
12
United States
Honor Health Research Institute
Scottsdale, Arizona, United States
City of Hope
Duarte, California, United States
UC Irvine - Chao Family Comprehensive Cancer Center
Orange, California, United States
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
UC San Francisco - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Start Date
September 28, 2018
Primary Completion Date
March 31, 2023
Completion Date
May 31, 2023
Last Updated
September 1, 2022
NCT07489378
NCT07181681
NCT07204340
NCT07403721
NCT07395258
NCT06885281
Lead Sponsor
Revolution Medicines, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions